HEALTH-RELATED QUALITY OF LIFE ON CÁNCER PATIENTS IN COLOMBIA
Author(s)
Romero M1, Gallo D1, Garzon A2, Chavez R3
1Fundación Salutia, Bogotá, Colombia, 2Fundación Simmon, Bogotá, Colombia, 3Universidad Jorge Tadeo Lozano, Bogotá, Colombia
OBJECTIVES: To evaluate the quality of life of patients with cancer METHODS: A descriptive cross-sectional study was carried out in the city of Bogotá, the measurement of quality of life was carried out through sociodemographic questions accompanied by a pain assessment scale and the application of the questionnaires EQ5D 3L and EORTC QLQ- C30. For the analysis of the information a database was constructed in Stata 14, where the sociodemographic variables, measured as categories, are expressed as absolute and relative frequencies; the continuous variables were calculated by arithmetic methods and the estimation of the quality of life was carried out according to the method explained in the questionnaires. RESULTS: The study population was 360 patients where the average age was 55.6 years, the predominant gender was female (59.9% n = 63) and the most frequent cancer was breast cancer (39.7% n = 31) presenting a level of quality of life of 0.73 where the VAS (analog visual scale) was 68.48. Chemotherapy predominated in the treatments received (33% n = 45) and in the stage of the disease the most frequent was controlled (53% n = 44). The result of the pain scale was 6.17, where the percentage of the population that responded having pain was (57% n = 47), indicating an average level of pain CONCLUSIONS: It is identified that the average quality of life was 0.68 with VAS of 66.63. This result brings some interest in promoting strategies within the health care model that gives importance to the perception of well-being of patients with these diseases.
Conference/Value in Health Info
2018-11, ISPOR Europe 2018, Barcelona, Spain
Value in Health, Vol. 21, S3 (October 2018)
Code
PCN367
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology